Printer Friendly

AFFYMAX APPOINTS VICE PRESIDENT OF RESEARCH AND DIRECTOR OF CHEMISTRY

AFFYMAX APPOINTS VICE PRESIDENT OF RESEARCH AND DIRECTOR OF CHEMISTRY
 PALO ALTO, Calif., April 14 /PRNewswire/ -- Affymax Research Institute announced today the appointment of Eric M. Gordon, Ph.D. as vice president of research and director of chemistry. Gordon will be responsible for all aspects of medicinal chemistry associated with Affymax's drug development and optimization programs.
 Gordon is an organic chemist with 16 years' experience in pharmaceutical development positions at Bristol-Myers Squibb. Most recently, Gordon served as a director of medicinal chemistry of the Bristol-Myers Squibb Pharmaceutical Institute in Princeton, N.J.
 "Eric brings tremendous experience and a record of accomplishment in drug development," said Gordon Ringold, president and scientific director of Affymax Research Institute. "Eric's appointment is a key step in the growth of our drug development and optimization capabilities."
 Affymax Research Institute, located in Palo Alto is the research arm of Affymax N.V. (NASDAQ: AFMXF), a Netherlands corporation headquartered in Amsterdam. Affymax is developing new technologies to accelerate the pace of drug discovery. Affymax is applying these technologies across a broad range of diseases to discover and develop products independently and in collaboration with pharmaceutical companies.
 -0- 4/14/92
 /CONTACT: Diana E. Kapp of Affymax, 415-496-2300/
 (AFMXF) CO: Affymax Research Institute ST: California IN: MTC SU: PER


RM-DG -- SJ001 -- 8062 04/14/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 14, 1992
Words:220
Previous Article:KING WORLD REPORTS RECORD SECOND QUARTER RESULTS
Next Article:MBNA CORPORATION REPORTS 16.2 PERCENT INCREASE IN NET INCOME; ANNOUNCES QUARTERLY DIVIDEND


Related Articles
AFFYMAX APPOINTS JIM YOUNG SENIOR VICE PRESIDENT FOR CORPORATE DEVELOPMENT
AFFYMETRIX APPOINTS TOP MANAGEMENT
AFFYMAX ANNOUNCES MANAGEMENT CHANGES
DuPont and Affymax Technologies Announce Collaborative Research And Development Agreement.
Affymax Names Andrew J. Perlman, M.D., Ph.D., Chief Executive Officer.
Affymax Appoints Helen S. Kim Chief Business Officer.
Affymax Appoints Daniel J. Levitt, M.D., Ph.D., as Chief Operating Officer And Head of Research and Development.
Affymax Appoints Arlene Morris President and Chief Executive Officer And Completes $20 Million Financing.
Affymax Appoints Vice President of Development and Director of Clinical Development.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters